Home›Trial›NCT06128629
🔬NCT06128629Phase 3RECRUITING

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Study Summary

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions / Drugs
NTLA-2001Placebo
View on ClinicalTrials.gov ↗
Sponsor
NTLA
Intellia Therapeutics
Gene Editing
D44/100
Study Details
Enrollment1200 participants
Primary Completion—
Lead SponsorIntellia Therapeutics
Data Retrieved2026-04-11 04:23:01.073878+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.